Gilead signs antibiotic development deal with CURx Pharmaceuticals

02/20/2014 | Genetic Engineering & Biotechnology News

Gilead Sciences and CURx Pharmaceuticals agreed to collaborate in the development of a broad spectrum combination antibiotic for the treatment of Pseudomonas aeruginosa lung infection, which affects cystic fibrosis patients. The drug, a combination of antibiotics fosfomycin and tobramycin, is ready to enter late-stage trials after yielding positive results in a midstage study involving CF patients with Pseudomonas aeruginosa infection.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA